90 related articles for article (PubMed ID: 20576220)
21. Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification.
de la Torre I; Valor L; Nieto JC; Hernández-Flórez D; Martinez L; Gonzalez CM; Monteagudo I; Longo JL; Montoro M; Carreño L
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):407-14. PubMed ID: 23763534
[TBL] [Abstract][Full Text] [Related]
22. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
24. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
[No Abstract] [Full Text] [Related]
25. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
26. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
27. Switching rheumatoid arthritis treatments: an update.
Atzeni F; Sarzi-Puttini P; Gorla R; Marchesoni A; Caporali R
Autoimmun Rev; 2011 May; 10(7):397-403. PubMed ID: 21262393
[TBL] [Abstract][Full Text] [Related]
28. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.
Mandema JW; Salinger DH; Baumgartner SW; Gibbs MA
Clin Pharmacol Ther; 2011 Dec; 90(6):828-35. PubMed ID: 22048227
[TBL] [Abstract][Full Text] [Related]
29. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.
Yazici Y; Yazici H
Clin Exp Rheumatol; 2008; 26(3):449-52. PubMed ID: 18578967
[TBL] [Abstract][Full Text] [Related]
31. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
[TBL] [Abstract][Full Text] [Related]
32. Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).
Iannone F; Ferraccioli G; Gremese E; Lapadula G;
Ann Rheum Dis; 2014 Jun; 73(6):e31. PubMed ID: 24368512
[No Abstract] [Full Text] [Related]
33. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
34. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
[TBL] [Abstract][Full Text] [Related]
35. Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.
Borrás-Blasco J; Navarro Ruiz A
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):71-9. PubMed ID: 25555555
[TBL] [Abstract][Full Text] [Related]
36. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
37. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
Morović-Vergles J
Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
Segal B; Rhodus NL; Patel K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
[TBL] [Abstract][Full Text] [Related]
39. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
40. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
Koike R; Takeuchi T; Eguchi K; Miyasaka N;
Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
